APSR Asthma
Assembly Virtual Meeting (AVM)
"Asthma Paradoxes"
Questions for panelists and their responses
to show / hide
response(s)
-
Whether FENO has any role in personalized treatment of asthma?
Response
Dr Hao-Chien Wang responds:
FeNO is a marker of eosinophilic inflammation & TH2 inflammation of airway. It could be used as a composite marker when we try to consider using biologics, another clinical application is to monitor the patient’s compliance of ICS.
-
How to control asthma in adult patient who always use reliever often? In which they don't want to use a controller due to iya cost
Response
Dr Hao-Chien Wang responds:
Considering over use (over reliance) of SABA, the most important thing is patient education: We should emphasize the importance of controller usage (for better symptom control, improved asthma related clinical outcomes, less healthcare resource utilization) and the risk of SABA overuse (poor asthma control, risk of acute exacerbation & increased mortality). Another strategy is try to use formoterol/ICS (anti-inflammatory reliever) for these patients (SMART approach).
-
Is there still a benefit of Montelukast for asthma patients?
Response
Dr Hao-Chien Wang responds:
Leukotriene modifier (Montelukast) has some role in asthma treatment:
- asthmatic with allergic rhinitis,
- exercise induced asthma,
- as add on therapy with other controllers (ICS, ICS+LABA) for better asthma control.
-
may i know at what stage of pregnancy you have recorded the high incidence of asthma symptoms?
Response
Dr Duminda Yasaratne responds:
usually at mid-second week. There were another few who developed symptoms close to term. Thanks.
